‘NOT REAL FOOD:' Doctor shows McDonald's burger that sat out 62 days
Dr. Robert DeBease kept a McDonald's hamburger and fries, and a Papa John's pepperoni pizza on his kitchen table for weeks and shared what they looked like — 62 days later.
'This 'food' refuses to rot… and that should terrify you,' he wrote in an Instagram post.
But if you expected the result to be something green and furry, think again.
The greasy takeout bag looks more worse for wear than the contents inside because aside from the food items looking rock hard, they appeared to all be intact, resembling what they would have looked like when they were first ordered.
'There's zero changes. There's no mold. There's no decay,' he said in the video post.
'Personally, I don't get it. If this was a piece of bread, it would be the colour of Kermit the Frog right now.'
'Why isn't this food rotting?' he asked, before answering himself: 'Well, probably because it's not real food.'
The Georgia-based naturopath and chiropractor likened the fries to a 'chemistry experiment' filled with chemicals designed to keep it looking fresh on the outside while slowing rotting you and I on the inside.
He then clarified not him because he doesn't eat this 'garbage.'
In his caption, DeBease noted how fast food is 'full of preservatives like calcium propionate, BHA, and TBHQ — chemicals that extend shelf life but destroy your health.'
He explained that while the additives used to preserve the food prevent mold from forming, they also disrupt hormones, increase body fat, worsen inflammation, cause autoimmune disease flare-ups, and damage gut microbiomes, adding that they are also 'filled with ultra-processed carbs and seed oils.'
McDonald's Canada testing a vegetable-based burger — again
Teen's kidneys failing after eating McDonald's Quarter Pounders: Report
McDonald's location bans anyone under 21 from dining inside due to 'student violence'
'If this food doesn't rot, maybe your body doesn't know how to break it down either,' he continued in his PSA.
DeBease added that if anything, people should opt to 'heal with real food' and to 'ditch fake food.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
2 hours ago
- NBC News
What happens when chatbots shape your reality? Concerns are growing online
As people turn to chatbots for increasingly important and intimate advice, some interactions playing out in public are causing alarm over just how much artificial intelligence can warp a user's sense of reality. One woman's saga about falling for her psychiatrist, which she documented in dozens of videos on TikTok, has generated concerns from viewers who say she relied on AI chatbots to reinforce her claims that he manipulated her into developing romantic feelings. Last month, a prominent OpenAI investor garnered a similar response from people who worried the venture capitalist was going through a potential AI-induced mental health crisis after he claimed on X to be the target of 'a nongovernmental system.' And earlier this year, a thread in a ChatGPT subreddit gained traction after a user sought guidance from the community, claiming their partner was convinced the chatbot 'gives him the answers to the universe.' Their experiences have roused growing awareness about how AI chatbots can influence people's perceptions and otherwise impact their mental health, especially as such bots have become notorious for their people-pleasing tendencies. It's something they are now on the watch for, some mental health professionals say. Dr. Søren Dinesen Østergaard, a Danish psychiatrist who heads the research unit at the department of affective disorders at Aarhus University Hospital, predicted two years ago that chatbots 'might trigger delusions in individuals prone to psychosis.' In a new paper, published this month, he wrote that interest in his research has only grown since then, with 'chatbot users, their worried family members and journalists' sharing their personal stories. Those who reached out to him 'described situations where users' interactions with chatbots seemed to spark or bolster delusional ideation,' Østergaard wrote. '... Consistently, the chatbots seemed to interact with the users in ways that aligned with, or intensified, prior unusual ideas or false beliefs — leading the users further out on these tangents, not rarely resulting in what, based on the descriptions, seemed to be outright delusions.' Kevin Caridad, CEO of the Cognitive Behavior Institute, a Pittsburgh-based mental health provider, said chatter about the phenomenon 'does seem to be increasing.' 'From a mental health provider, when you look at AI and the use of AI, it can be very validating,' he said. 'You come up with an idea, and it uses terms to be very supportive. It's programmed to align with the person, not necessarily challenge them.' The concern is already top of mind for some AI companies struggling to navigate the growing dependency some users have on their chatbots. In April, OpenAI CEO Sam Altman said the company had tweaked the model that powers ChatGPT because it had become too inclined to tell users what they want to hear. In his paper, Østergaard wrote that he believes the 'spike in the focus on potential chatbot-fuelled delusions is likely not random, as it coincided with the April 25th 2025 update to the GPT-4o model.' When OpenAI removed access to its GPT-4o model last week — swapping it for the newly released, less sycophantic GPT-5 — some users described the new model's conversations as too ' sterile ' and said they missed the ' deep, human-feeling conversations ' they had with GPT-4o. Within a day of the backlash, OpenAI restored paid users' access to GPT-4o. Altman followed up with a lengthy X post Sunday that addressed 'how much of an attachment some people have to specific AI models.' Representatives for OpenAI did not provide comment. Other companies have also tried to combat the issue. Anthropic conducted a study in 2023 that revealed sycophantic tendencies in versions of AI assistants, including its own chatbot Claude. Like OpenAI, Anthropic has tried to integrate anti-sycophancy guardrails in recent years, including system card instructions that explicitly warn Claude against reinforcing 'mania, psychosis, dissociation, or loss of attachment with reality.' A spokesperson for Anthropic said the company's 'priority is providing a safe, responsible experience for every user.' 'For users experiencing mental health issues, Claude is instructed to recognize these patterns and avoid reinforcing them,' the company said. 'We're aware of rare instances where the model's responses diverge from our intended design, and are actively working to better understand and address this behavior.' For Kendra Hilty, the TikTok user who says she developed feelings for a psychiatrist she began seeing four years ago, her chatbots are like confidants. In one of her livestreams, Hilty told her chatbot, whom she named 'Henry,' that 'people are worried about me relying on AI.' The chatbot then responded to her, 'It's fair to be curious about that. What I'd say is, 'Kendra doesn't rely on AI to tell her what to think. She uses it as a sounding board, a mirror, a place to process in real time.'' Still, many on TikTok — who have commented on Hilty's videos or posted their own video takes — said they believe that her chatbots were only encouraging what they viewed as Hilty misreading the situation with her psychiatrist. Hilty has suggested several times that her psychiatrist reciprocated her feelings, with her chatbots offering her words that appear to validate that assertion. (NBC News has not independently verified Hilty's account). But Hilty continues to shrug off concerns from commenters, some who have gone as far as labeling her 'delusional.' 'I do my best to keep my bots in check,' Hilty told NBC News in an email Monday, when asked about viewer reactions to her use of the AI tools. 'For instance, I understand when they are hallucinating and make sure to acknowledge it. I am also constantly asking them to play devil's advocate and show me where my blind spots are in any situation. I am a deep user of Language Learning Models because it's a tool that is changing my and everyone's humanity, and I am so grateful.'
Associated Press
3 hours ago
- Associated Press
A.D.A.M. Consumer Health Successfully Maintains URAC Certification; Reinforces Commitment to Quality and Excellence
JOHNS CREEK, Ga., Aug. 13, 2025 /PRNewswire/ -- A.D.A.M. Consumer Health (A.D.A.M.), part of the global Ebix Group, has successfully passed and maintained its URAC Health Content Provider Certification — a significant milestone underscoring the company's commitment to providing credible, high-quality, and trusted health information to consumers. A.D.A.M was one of the first organizations to receive URAC Health Website Accreditation in 2001. Maintaining URAC certification for the past 24 consecutive years ensures that A.D.A.M. Consumer Health products are aligned with benchmarks of transparency, editorial integrity, and patient empowerment. A.D.A.M. has shown continued leadership in health education solutions, medical illustrations, and evidence-based content development. With a client base that includes hospitals, healthcare providers, educational institutions, insurance organizations, and other digital platforms globally, A.D.A.M. remains a cornerstone in the Ebix Group's healthcare content and eLearning vertical. Commenting on this achievement, Ashish Jaitly ED & CEO, Global Technology Business, stated: 'Maintaining the URAC Certification in such a dynamic operational environment is an achievement and we are truly proud of it. This reaffirms the trust placed in A.D.A.M. by our global customers and strengthens our ability to offer high-integrity content that educates and empowers users.' A.D.A.M. continues to strengthen their footprint in health and wellness, this certification reinforces A.D.A.M.'s position as a trusted global content leader, advancing healthcare literacy and digital enablement at scale. About URAC Health Content Provider Certification: URAC's Health Content Provider Certification, administered by the Washington D.C.-based independent accreditation organization is a prestigious U.S.-based accreditation globally respected for its rigorous standards in consumer-facing health content. It serves as a gold standard for verifying that published health information is evidence-based, medically accurate, current, and developed under strict editorial oversight by qualified healthcare professionals. The certification process includes a comprehensive evaluation of content development protocols, editorial policies, update frequency, and quality assurance mechanisms—ensuring alignment with evolving healthcare standards and safeguarding against misinformation in today's digital landscape. While grounded in U.S. healthcare practices, URAC's accreditation is valued internationally as a benchmark of credibility, integrity, and trust. For organizations like A.D.A.M. Consumer Health, maintaining this certification reflects a deep commitment to public health education, editorial excellence, and the delivery of reliable, transparent medical content that empowers informed healthcare decisions. About A.D.A.M. A.D.A.M. is headquartered in Johns Creek, Georgia. A.D.A.M. is a business unit of Ebix Inc. and for over two decades, has been a leading developer of interactive health and medical information for websites, consumer health portals, healthcare, insurance, biomedical, medical device, pharmaceutical and academic organizations. A.D.A.M.'s products combine physician-reviewed text, medical illustrations, multimedia, and interactive tools and technology that explain complex medical and health information in a consumer-friendly manner. For more information, visit CONTACT: [email protected] View original content to download multimedia: SOURCE EBIX INC
Forbes
3 hours ago
- Forbes
InnovationRx: Shooting At The CDC Highlights The Perils Of Health Misinformation
In this week's edition of InnovationRx, we look at the shooting at the CDC, longevity drugs for dogs (and maybe eventually people too), Strand Therapeutics' programmable mRNA for fighting cancer, Tahoe Therapeutics' AI models of living cells, and more. To get it in your inbox, subscribe here. CDC's Atlanta campus getty On Friday evening, a 30-year-old man who believed the COVID-19 vaccine had made him ill fired hundreds of bullets on the Centers for Disease Control and Prevention's Atlanta headquarters. A DeKalb County police officer was killed in the attack. The shooting followed years of conspiracy theories and misinformation about vaccines. Christa Capazzola, the CDC's acting chief operating officer, called the shooting 'a targeted attack on CDC related to COVID' in a Saturday email addressed to the agency's employees. A union representing CDC workers called on federal officials to condemn misinformation about vaccines. Attacks on science have increased since President Trump took office in January, and his HHS Secretary Robert F. Kennedy Jr. has sought to blame the CDC for the pandemic. In 2021, he falsely called the COVID shots the 'deadliest vaccine ever made.' Then, last week, the Trump Administration canceled almost $500 million in contracts to develop mRNA vaccines that could protect against future infectious disease outbreaks or pandemics to the horror of public health experts. On Saturday, the day after the shooting, National Institutes of Health director Jay Bhattacharya appeared on Steve Bannon's 'War Room' podcast to claim that the public didn't trust mRNA technology—without commenting on the role he or his boss played in that. On a call with the staff of the National Center for Immunization and Respiratory Diseases, CDC employees recounted harrowing experiences during the shooting and asked about the misinformation that may have influenced the shooter, according to reporting by Stat. One employee, struggling to hold back tears, said that she had been sheltering in place during the attack and didn't feel safe until she saw the SWAT team. 'So I think it would be helpful to know what went right so that we feel like we weren't just sitting ducks,' she said. Startup Loyal Is Working On A Longevity Pill For Dogs – And Maybe Someday For Humans, Too Loyal's Celine Halioua Ethan Pines for Forbes D ogs don't live long enough. Celine Halioua – an Oxford Ph.D. dropout and former chief of staff at the first venture capital fund focused on longevity-related biotechs – thinks they deserve a few more years. She's spent the last nearly six years building Loyal, a San Francisco startup developing drugs to delay canine aging by targeting metabolic and hormonal imbalances before they become disease. The company's first beef-flavored longevity pill could hit the market by 2026, potentially extending dogs' lives–and perhaps someday ours as well. 'I realized that to do this in humans would take billions of dollars, patent issues and trauma, but you could do it in dogs,' says Halioua, 30, whose own dog, Della, is a senior Rottweiler mix that she adopted three years ago. Loyal doesn't have any revenue yet, but Halioua is in conversations with the FDA and has cleared early hurdles. Under the agency's conditional approval program for innovative veterinary drugs, Halioua hopes to get the okay to be on the market with its first drug, which changes the metabolism of senior dogs (ages 10 and up) to mimic a low-calorie diet, which has been shown to extend their lives, next year. Loyal also has both a shot and a pill in the works to lengthen large dogs' short lifespans by limiting a growth hormone more prevalent in big dogs than small. Halioua has raised $135 million equity from top investors that include Bain Capital, First Round, Khosla Ventures and Valor Equity Partners at a valuation of $425 million. The market is potentially enormous: There are nearly 90 million dogs across some 60 million households in the United States, according to the American Veterinary Medical Association. Last year those households spent an average of $1,852 on their pups, a 6% increase over 2023. Loyal's drugs have the potential to quickly generate hundreds of millions in revenue, should they get the regulatory nod. Beyond that, Loyal hopes that its success with dogs will someday open an even bigger market: people. That's a herculean task given the cost and time it might take to develop a human longevity drug and get it approved. But Halioua thinks the science will ultimately win out. 'I think the general public will be blown away when they realize they can go to the vet and get a drug to extend their dogs' lifespan,' she says. 'Then they'll get like, 'Why can't I do this for my grandma?'' Read more here. BIOTECH AND PHARMA Strand Therapeutics raised $153 million led by Swedish investment giant Kinnevik to make cancerous tumors light up, making them reveal themselves to the body's immune system. The deal, at an estimated $550 million valuation, followed early clinical results showing its programmable mRNA shrank patients' tumors who were out of other treatment options. 'It shocked even us,' Strand cofounder and CEO Jake Becraft told Forbes. Read the whole story here. DIGITAL HEALTH AND AI One of the holy grails of biology is digitally simulating a living cell. If researchers can use computers to more accurately understand how new medicines would react in the body, that could give them greater confidence when they're tested on animals and humans. But the missing piece of making this a reality is data. Tahoe Therapeutics got one step closer to that goal with the February release of Tahoe-100M, a collection of 100 million different datapoints showing how different kinds of cancer cells responded to interactions with more than 1,000 different molecules. This type of data is crucial to training AI models, because information on how cells respond to various molecules improves an algorithm's ability to predict how they'll be affected by others. This week, Tahoe announced $30 million in new venture funding, led by Amplify Partners, bringing the company's total funding to $42 million and its valuation to $120 million. 'Our core superpower is the ability to generate the massive datasets required for virtual cell models,' CEO Nima Alidoust told Forbes. Read the whole story here. PUBLIC HEALTH AND HOSPITALS Annals of Internal Medicine published a large-scale study of more than 1.2 million children over the course of 23 years to determine if aluminum in vaccines is related to any chronic disorders in July. The study found no evidence of such a link, highlighting both the safety and effectiveness of childhood vaccines. HHS Secretary Kennedy critiqued the study's methodology and demanded its retraction, something that the journal refused to do. The publication Unbiased Science, written by public health scientists, has an excellent breakdown of the study and explains why Kennedy's critique is flawed. Plus : A preliminary study suggests that bird flu (H5N1) may be airborne on dairy farms. NEXT BILLION-DOLLAR STARTUPS Twenty of the 25 companies on this year's Forbes' Next Billion-Dollar Startups list of VC-backed startups we think most likely to become worth $1 billion or more are focused on artificial intelligence. Three of them–Collate, Assort Health and AcuityMD–use AI to improve operations in healthcare. Assort Health sells a text-to-voice artificial intelligence chatbot to search physicians' calendars to match their openings with the type of appointment required, cutting wait times on millions of inbound calls to medical groups. Acuity MD uses AI to sift through de-identified records, helping medical device manufacturers connect to physicians whose patients might benefit from different products. And Collate, which came out of stealth in January, uses AI to automate the paperwork required for life sciences companies, such as that for clinical trials and FDA approval. 'This stuff they would have spent months doing we can do over the course of days,' says cofounder and CEO Surbhi Sarna. See the full 2025 list here. WHAT WE'RE READING Trump delayed a change on Medicare's coverage of pricey bandages after a health company that makes them donated millions to political action committee MAGA, Inc. As GLP-1 drugs shrink appetites, some restaurants are offering miniature meals and tiny tasting menus. Eli Lilly's much-anticipated obesity pill, called orforglipron, fell short of Zepbound and Wegovy, leading to 11% weight loss in a late-stage clinical trial. The company's stock plummeted on the news and hadn't recovered as of Tuesday's market close. Why Trump's firing of the Bureau of Labor Statistics commissioner also puts crucial health data at risk. A new study published this week found encouraging early results for a cancer vaccine in patients with pancreatic and colorectal cancer, two indications that are difficult to treat. AbbVie plans to spend $195 million on a facility to manufacture active pharmaceutical ingredients at its campus north of Chicago. The FDA approved Boehringer Ingelheim's zongertinib, an oral lung cancer treatment for patients with HER2 mutations. MORE FROM FORBES Forbes How AI Data Centers Could Save California's High-Speed Rail Project Forbes Inside The Richest Presidential Cabinet Ever Forbes Zuckerberg Squandered His AI Talent. Now He's Spending Billions To Replace It.
